佐力药业
(300181)
| 流通市值：104.85亿 | | | 总市值：121.97亿 |
| 流通股本：6.03亿 | | | 总股本：7.01亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,279,713,382.85 | 1,599,453,446.18 | 824,425,237.08 | 2,577,878,166.87 |
| 营业收入 | 2,279,713,382.85 | 1,599,453,446.18 | 824,425,237.08 | 2,577,878,166.87 |
| 二、营业总成本 | 1,720,477,214.14 | 1,184,629,333.23 | 623,213,469.79 | 2,050,169,103.69 |
| 营业成本 | 865,634,716.16 | 591,633,075.58 | 322,376,359.19 | 1,006,601,043.75 |
| 税金及附加 | 22,027,818.71 | 16,078,787.42 | 6,322,257.02 | 29,056,520.72 |
| 销售费用 | 706,537,994.76 | 499,570,202.69 | 256,281,862.95 | 838,702,179.12 |
| 管理费用 | 77,841,865.65 | 48,542,499.49 | 23,478,495.24 | 110,378,725.35 |
| 研发费用 | 41,831,115.46 | 25,248,204.1 | 13,423,922.11 | 71,938,052.87 |
| 财务费用 | 6,603,703.4 | 3,556,563.95 | 1,330,573.28 | -6,507,418.12 |
| 其中:利息费用 | 10,619,729.55 | 6,664,349.9 | 2,784,981.17 | 9,289,184.83 |
| 其中:利息收入 | 4,147,479.09 | 3,200,466.43 | 1,488,351.86 | 15,953,231.8 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -2,184,112.19 | -1,339,602.32 | -292,960.5 | -662,074.01 |
| 资产处置收益 | 33,840.38 | - | - | 352,220.71 |
| 资产减值损失(新) | -3,272,832.21 | -3,272,832.21 | 686,021.49 | -12,198,929.71 |
| 信用减值损失(新) | -10,277,114.58 | -7,846,240.46 | -9,748,235.25 | -6,566,372.99 |
| 其他收益 | 74,205,638.39 | 49,217,299.78 | 23,926,335.87 | 100,653,614.62 |
| 四、营业利润 | 617,741,588.5 | 451,582,737.74 | 215,782,928.9 | 609,287,521.8 |
| 加:营业外收入 | 136,995.52 | 102,740.03 | 70,331.63 | 708,358.65 |
| 减:营业外支出 | 7,118,333.72 | 3,790,700.61 | 2,116,208.65 | 13,303,138.51 |
| 五、利润总额 | 610,760,250.3 | 447,894,777.16 | 213,737,051.88 | 596,692,741.94 |
| 减:所得税费用 | 92,648,589.48 | 68,701,685.54 | 30,350,870.36 | 80,734,655.22 |
| 六、净利润 | 518,111,660.82 | 379,193,091.62 | 183,386,181.52 | 515,958,086.72 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 518,111,660.82 | 379,193,091.62 | 183,386,181.52 | 515,958,086.72 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 509,974,478.8 | 373,500,159.82 | 181,151,432.46 | 507,771,934.85 |
| 少数股东损益 | 8,137,182.02 | 5,692,931.8 | 2,234,749.06 | 8,186,151.87 |
| 扣除非经常损益后的净利润 | 508,517,732.85 | 371,685,120.24 | 181,204,268.22 | 507,684,220.81 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.73 | 0.53 | 0.26 | 0.73 |
| (二)稀释每股收益 | 0.73 | 0.53 | 0.26 | 0.73 |
| 八、其他综合收益 | 193,161,979.42 | 266,901,782.73 | 122,157,526.18 | 56,170,995.22 |
| 归属于母公司股东的其他综合收益 | 178,682,557.44 | 246,894,825.1 | 113,000,598.02 | 51,960,417.42 |
| 九、综合收益总额 | 711,273,640.24 | 646,094,874.35 | 305,543,707.7 | 572,129,081.94 |
| 归属于母公司股东的综合收益总额 | 688,657,036.24 | 620,394,984.92 | 294,152,030.48 | 559,732,352.27 |
| 归属于少数股东的综合收益总额 | 22,616,604 | 25,699,889.43 | 11,391,677.22 | 12,396,729.67 |
| 公告日期 | 2025-10-28 | 2025-08-20 | 2025-04-25 | 2025-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |